128120-93-4

Basic information

• Product Name: (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester
• Synonyms: (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester
• CAS NO: 128120-93-4
• Molecular Weight: 412.28
• Mol File: 128120-93-4.mol
• Article Data: 41

Chemical Properties

• CAS DataBase Reference: (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester(128120-93-4)
• EPA Substance Registry System: (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester(128120-93-4)

Safety Data

• Hazardous Substances Data: 128120-93-4(Hazardous Substances Data)

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 147-85-3 L-proline 
• 364750-81-2 N-tert-Butyloxycarbonyl-(2S,4S)-4-methylproline 
• 99-73-0 para-bromophenacyl bromide 
• 99-90-1 para-bromoacetophenone 

Downstream Products

• 1250939-45-7 (2S,4S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1419386-60-9 C₃₄H₃₇F₅N₄O₆S 
• 1419386-62-1 C₃₉H₄₉BF₂N₄O₅ 
• 1419384-78-3 C₄₇H₅₈F₂N₈O₆ 
• 1419387-22-6 C₃₄H₃₉F₃N₄O₆S 
• 1419384-89-6 C₅₂H₆₂N₈O₆ 
• 1419385-09-3 C₅₁H₆₂N₈O₆ 
• 1419389-51-7 C₃₃H₃₇F₃N₄O₆S 
• 1419385-31-1 C₅₀H₆₀N₈O₆ 
• 1419391-47-1 C₄₇H₅₇N₅O₅ 
• 1419385-72-0 C₅₁H₆₃N₇O₇ 

Relevant articles and documents

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Synthesis method of starting raw material for daclatasvir

The invention relates to a synthesis method of a starting raw material for daclatasvir. The synthesis method comprises the following steps of enabling 2,4'-dibromoacetophenone as shown in a formula I,L-BOC-proline as shown in a formula II, potassium carbo

Hepatitis c polymerase inhibitors

The invention relates to a 4,4'-bis(2-((S)-pyrrolidine-2-yl)-1H-imidazole-4-yl)biphenyl type compound and a derivative therefore. The compound disclosed by the invention is a hepatitis c virus (HCV) polymerase inhibitor, has HCV resistant activity and can